Immunomodulatory therapies in sepsis

Intensive Care Medicine, Supplement

Volumn 26, Issue 1, 2000, Pages

  Kox, W J ^a   Volk, T ^a   Kox, S N ^a   Volk, H D ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Critical illness; Immune function; Immune therapy; Inflammation; Sepsis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MODEL; HUMAN; INFLAMMATION; INTENSIVE CARE; NONHUMAN; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK;

ANIMALS; CRITICAL CARE; CRITICAL ILLNESS; CYTOKINES; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MONOCYTES; SEPSIS;

EID: 0034108730     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. ACCP-SCCM Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874
2. Ectenacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/ cachectin for recovery from experimental peritonitis. J Immunol 145: 3762-3766
3. Pfeffer K (1993) Mice deficient for the p55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457-467
4. Faist E, Kim C (1998) Therapeutic immunomodulatory approaches for the control of systemic inflammatory response syndrome and the prevention of sepsis. New Horiz 6: S97-S102
5. Dinarello CA (1997) Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112: 321S-329S
6. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653-658
7. Cronin L, Cook DJ, Heyland DK, King D, Lansang MA, Fisher CJ (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23: 1430-1439
8. Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis and septic shock: a metaanalysis. Crit Care Med 23: 1294-1439
9. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1110
10. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study. Crit Care Med 21: 318-327
11. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M (1995) CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokineconcentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 23: 1461-1469
12. Abraham E, Wunderink R, Silverman H (1995) Monoclonal antibody to human tumor necrosis factor alpha (TNF-c Mab): efficacy and safety in patients with the sepsis syndrome. JAMA 273: 934-941
13. Abraham E, Anzueto A, Gutierrez, Tessler S, San Pedro, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351: 929-933
14. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24: 1431-1440
15. Clark MA, Plank LD, Connolly AB, Streat SJ, Hill AA, Gupta, R, Monk DN, Shenkin A, Hill GL (1998) Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis - a randomized, clinical trial. Crit Care Med 26: 1650-1659
16. Reinhart K, Wiegand Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733-742
17. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702
18. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25: 1115-1124
19. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843
20. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 22: 12-21
21. Astiz ME, Rackow EC (1998) Septic shock. Lancet 351: 1501-1505
22. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120: 771-783
23. Abraham E (1999) Why immunotherapies have not worked in sepsis. Int Care Med 25: 556-566
24. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivation in septic patients: restoration by IFN gamma treatment. Nat Med 3: 678-681
25. van Dissel J, van Langevelde P, Westendorp RG, Kwappenber K, Frolich M (1998) Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351: 950-953
26. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115: 457-469
27. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921
28. Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128
29. Munoz C, Carlet C, Fitting B, Bleriot J, Cavaillon J (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88: 1747-1754
30. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD (1995) Mechanism of endotoxin desensitization - involvement of IL-10 and transforming growth factor beta. J Exp Med 5: 1887-1892
31. Zedler S, Bone RC, Baue AE, vDoonersmarck GH, Faist E (1999) T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 27: 66-72
32. Marie C, Muret J, Fitting C, Losser MR, Payen D, Cavaillon JM (1998) Reduced ex vivo interleukin-8 production by neutrophils in septic and non-septic systemic inflammatory response syndrome. Blood 91: 3439-3446
33. Simms HH, Damico R (1994) Polymorphonuclear leukocyte dysregulation during the systemic inflammatory response syndrome. Blood 83: 1398-1407
34. Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24: 381-384
35. Weiss M, Moldawer LL, Schneider M (1999) Granulocyte colony-stimulating factor to prevent the progression of systemic non-responsiveness in systemic inflammatory response syndrome and sepsis. Blood 93: 425-439
36. Nelson S, Belknap SM, Carlson RW, Dale D, deBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, Root R, Wilson J for the CAP study group (1998) A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 178: 1075-1080
37. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wernet P (1995) Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 10: 21-26
38. Volk HD, Reinke P, Falck P (1989) Diagnostic value of an immune monitoring program for the clinical management of immunosupressed patients with septic complications. Clin Transplant 3: 246-252
39. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, Docke WD, Kox WJ (1996) Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 :S474-S481
40. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD (1997) Interferon gamma 1 b in the treatment of compensatory anti inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157: 389-393
41. De Werra I, Jaccard C, Corradin SB Chiolero R, Yersin B, Gallati H, Assicot M, Bohuon C, Baumgartner JD, Glauser MP, Heumann D (1997) Cytokines, nitrite, soluble TNF receptors, and procalcitonin concentrations: comparison in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 25: 607-613